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Abstract
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer and the third
cause of cancer related death worldwide. Liver cancer is the result of repeated injuries
to the liver triggered by different causes. Currently, sorafenib is the only drug U.S.
Food and Drug Administration approved targeted therapy. Sorafenib, an oral
multikinase inhibitor, which inhibits the proliferation of tumor cells and blocks
angiogenesis. Sorafenib has been shown to treat early and mild HCC lesions and it
helped increase the survival rates at one year, but for only 44% of patients.
Chemotherapies are an important line of defense when it comes to cancer. HCC,
however, is been proven to be chemo-resistant and the side effects of chemotherapies
lower the quality of life for cancer patients due to their non-selective cytotoxicity.
Thus, the search for better HCC treatment options is essential.
A carcinogenesis model that mimics the human disease was developed here to test the
effects of crocin, one of the major bioactive molecules found in saffron. Crocin, is a
natural compound with strong-anti-oxidant, hepatoprotective, and anti-inflammatory
effects. Crocin has been shown to kill different cancers in vitro.
In this study and compared to monotherapy, combination therapy (crocin + sorafenib)
that simultaneously targeted multiple pathways and provided a better treatment option.
The effects of crocin was investigated on DEN induced HCC in male Wistar rats.
Crocin has been found to be involved in the mitochondrial, apoptotic pathway
triggering cell death and tumor suppression. This study highlights crocin’s therapeutic
effects against HCC both as a single agent and in combination with sorafenib.

Keywords: Hepatocellular carcinoma, crocin, sorafenib, apoptosis, cancer, chemo
resistance, chemotherapy.
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)Title and Abstract (in Arabic

تقييم اإلمكانيات العالجية للكروسين ضد سرطان الكبد المستحث كيميائيا ً في الجرذان
الملخص

سرطان الكبد هو خامس أكثر أنواع السرطان شيوعا والسبب الثالث للوفاة المرتبطة
بالسرطان في جميع أنحاء العالم .سرطان الكبد هو نتيجة لتعرض الكبد إلصابات متكررة بسبب
عدة محفزات .حاليًا  ،العالج الوحيد المعتمد من قبل إدارة الغذاء و الدواء األمريكيه هو العالج
الكيماوي بدواء السورافينب هو العالج المستهدف الوحيد المعتمد من قبل إدارة الغذاء والدواء
األمريكية هذا العالج يعمل على منع تكاثر الخاليا السرطانية ومنع توليد األوعية .لقد ثبت أن
السورافينب يعالج اآلفات المبكرة لسرطان الكبد وساعد على زيادة معدالت البقاء على قيد الحياة
لمدة عام واحد ل  ٪ 44فقط من المرضى .العالجات الكيميائية هي خط الدفاع األول عندما يتعلق
الكيميائي ،كما أن
األمر بالسرطان .ومع ذلك  ،فقد ثبت أن سرطان الكبد يقوم بمقاومة العالج
ً
اآلثار الجانبية للعالجات الكيميائية تقلل من جودة حياة مرضى السرطان بسبب تسممهم الخلوي
غير االنتقائي .وبالتالي  ،فإن البحث عن خيارات أفضل لعالج سرطان الكبد هو أمر ضروري.
الكروسين ،مركب حيوي في الزعفران المعروف بقدرته في قتل أنواع مختلفة من الخاليا
السرطانية في المختبر .مقارنة بالعالج األحادي ،يعمل العالج المركب بين الكروسين و
السورافينب باستهداف مسارات متعددة في وقت واحد .في هذا البحث يتم تسليط الضوء على
اآلثار العالجية للكروسين ضد سرطان الكبد .تم استخدام نموذج سرطنه يحاكي المرض في البشر.
نتائج البحث تشير إل ى أن الكروسين يعمل على تفعيل موت الخلية المبرمج و يعمل على تثبيط
تكاثر الخاليا السرطانية.
مفاهيم البحث الرئيسية :سرطان الكبد ،كروسين ،سورافينب ،موت الخلية المبرمج ،تكاثر
الخاليا ،مقاومة العالج الكيماوي ،العالج الكيماوي.
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Chapter 1: Introduction
1.1 Cancer
Cancer is a disease characterized by uncontrolled cell division and growth.
Cells are the building blocks of the human body. They are controlled by a variety of
signaling pathways that monitor their growth, reproduction, and death.
Cell death is a vital process in maintaining homeostasis, however, in the case
of cancer, a single cell skips the signal for cell death and starts to divide and proliferate
uncontrollably. Cancer cells are often capable of turning on signals required for their
own growth and survival (Figure 1; Hanahan & Weinberg, 2011) including the
formation of new blood vessels to supply the oxygen and nutrients needed to form and
maintain tumors. These tumors have the ability to invade neighboring tissues and
organs, therefore changing the normal anatomy and physiology of different organs and
organ systems that ultimately leads to aberrant homeostasis.
Several factors contribute to the development of cancer including exposure to
certain chemicals & radiation, family history, and smoking. Many types of cancers are
treatable and can even be prevented if healthy lifestyle was adopted (Porta & Last,
2018). According to the International Agency for Research on Cancer there were 14.1
million cases of cancer and 8.2 million deaths worldwide in 2012 (Ferlay et al., 2015).
Despite all efforts, the latest global cancer data reported a notable rise in cancer cases
with an estimate of 18.1 million new cases and 9.6 million deaths in 2018, thus ranking
cancer the second leading cause of death worldwide (Bray et al., 2018). In the United
Arab Emirates (UAE), approximately 4500 new cancer cases are reported annually
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making cancer the third leading cause of death in Abu Dhabi with an estimate of
around 427 deaths in 2015 according to the UAE Department of Health.

Figure 1: Hallmarks of cancer
Source: (Hanahan & Weinberg, 2011)

1.2 The Liver
The liver is the largest solid internal organ in the body measuring at about 1.2
to 1.6 kg, which accounts for approximately 2% to 3% of average body weight. The
liver is located in the right upper quadrant of the abdominal cavity. It is divided into
two lobes by the external marking of the falciform ligament (Abdel-Misih &
Bloomston, 2010). The liver is considered as the major filter of the body as it is
responsible for eliminating any harmful chemicals and represents the main regulatory
site for metabolism. In addition to synthesizing many proteins and enzymes, the liver
is also in charge of the uptake, processing, and distribution of nutrients throughout the
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body. Complex interactions of different cell types help the liver carrying out its
function including hepatocytes, oval cells, and kupffer cells (Hoekstra et al., 2013).

1.2.1 Hepatocellular Carcinoma
Liver cancer differs according to the type of cells that are involved. They
include hepatocellular carcinoma (HCC), cholangiocarcinoma and angioscarcoma.
The progression of liver cancer starts with frequent insult to the liver due to several
factors. Repeated insults to the liver will cause acute inflammation, when it persists it
will lead to fibrosis and cirrhosis and eventually the formation of hepatic neoplasms.
HCC is the most prevalent type of primary liver cancer with 782000 cases diagnosed
and 746000 deaths in 2012 in the United States alone. HCC is ranked as the fifth most
common type of cancer and the third cause of cancer related deaths worldwide (Forner
et al., 2018). The incidence of liver cancer at UAE is rising due to the increased number
of patients suffering from liver diseases that when left untreated would progress into
liver cancer. Liver cancer is the fourth cause of cancer related deaths for both genders
in the UAE (Figure 2; Department of Health – Abu-Dhabi, 2015). The escalating
incidence of liver cancer is attributed to multiple risk factors including alcoholic
consumption, fatty liver disease, viral hepatitis C and B. As it is the case of most
cancers, chemotherapy is the first line of defense. Chemotherapeutic drugs used to
treat HCC include cisplatin, doxorubicin and mitomycin. All those drugs aim to
increase the survival and rarely do they reverse the course of cancer development. One
of the major challenges with chemotherapies is their non-selective cytotoxicity
(Subramaniam et al., 2013). Patients with the best prognosis are the ones who detect
their cancer at early stages and opt for surgical resection of the tumor and undergoing
liver transplantation. In most cases, however, patients are diagnosed with liver cancer

4
at late stages where intervention opportunities are limited and not very effective in
most cases (Forner et al., 2018).

Figure 2: Leading causes of deaths related to cancer in the United Arab Emirates –
Abu Dhabi in men and women
Source: (Department of Health – Abu-Dhabi, 2015)

1.3 Sorafenib
Sorafenib is the only U.S. Food and Drug Administration (FDA) approved
targeted therapy for HCC. Sorafenib, an oral multikinase inhibitor, blocks tumor cell
proliferation by targeting Raf/MEK/ERK signaling and inhibits angiogenesis by
targeting vascular endothelial growth factor (VEGF) and platelet-derived growth
factor (PDGF) receptors (Subramaniam et al., 2013). Despite the benefit provided by
sorafenib, the need for additional advanced HCC treatment options is much needed.
Compared with monotherapy, combination therapy targeting multiple signaling
pathways may be a better treatment option by providing a way to potentially
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circumvent resistance, feedback activation, and compensatory activation of prosurvival pathways.

1.4 Plants in Medicine
Historically humans have relied on plant bases remedies to cure illnesses,
manage diseases, and relieve pain since approximately 60,000 years ago. Many
countries have used traditional medicine as their primary source of health care. Many
of the plants and plant based products that are used in traditional medicine have been
adapted and integrated into the current commercial drug manufacturing market
(Prinsloo et al., 2018). Many plants possess anti-inflammatory, anti-oxidative
properties that make them potent treatment options for many disorders. (Adegbola et
al., 2017). Plants play an essential role in improving the prognosis of patients. Today,
50% of the clinically used drugs have originated from plants and their derivatives (Koo
et al., 2018). Research showed that specific components in plant foods have the ability
to alter DNA methylation levels therefore influencing genome stability and
transcription of tumor suppressors and oncogenes (Ferguson et al., 2015).

1.4.1 Plants in Cancer Treatment
The National Cancer Institute (NCI) has discovered the anti-cancer potential of
3000 plant species. Plants have been wildly studied and researched for uncover their
anti-cancer activities and interactions with other drugs. A new paradigm shifts in
modern medicine is currently underway to utilize specific plants as enhancers of
chemotherapeutic agents or even substituting chemotherapy altogether. Research is
uncovering the pro-apoptotic, anti-inflammatory, anti-angiogenic, and anti-oxidant
potential all in which aid in arresting the progression of cancer (Desai et al., 2008).
Review study suggested that detailed analysis to explore the synergisms, effects,
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bioavailability, and dose optimization for different herbal treatments is still an area
that requires extensive research. Preliminary data from recent clinical trials using
phytochemicals and plant extracts for cancer prevention and therapy show promising
results (Block et al., 2015).

1.4.1.1 Saffron
Saffron is the most expensive spice in the world. Each flower has three stigmas
(Figure 3). Due to the delicate nature of the stigmas and their flowers, they must be
hand-picked or they will lose their color and aroma. It comes from the flower of Crocus
sativus L. Iridaceae. The main bioactive molecules found in saffron are carotenoid;
crocin, and carotenoid’s degradation products; picrocrocin, and safranal. These are
responsible for saffron’s distinctive color, taste and aroma, respectively. Saffron is
mainly cultivated in Iran, Afghanistan, Turkey, and Spain. Saffron petals have shown
potential in traditional medicine as anti-spasmodic, stomachic, curing anxiety.
Pharmacological properties of saffron include its anti-bacterial, immunostimulator,
anti-hypertensive, and antidepressant properties, it also helps relaxing muscles
(Khazdair, et al., 2015).

Figure 3: Every C.sativus L.flower has three stigmas
Source: (Andabjadid et al., 2015)
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1.4.1.2 Crocin
Crocetin di-gentiobiose ester known as Crocin has been found to be the primary
compound in saffron. Crocin is one of the few carotenoids that are water soluble.
Crocin demonstrates many pharmacological properties and have been confirmed as a
powerful antioxidant and anti-inflammatory effects (Mashmoul et al., 2013).
Treatments with crocin and cisplatin individually or jointly on osteosarcoma cells
MG63 and OS732 cells showed a strong killing effect on osteosarcoma cells and
suppressed the ability of invasion of MG63 cells which leads to the up-regulation of
the expression of caspase-3 and caspase-8 all of which are markers that indicate the
activation of apoptosis (Min et al., 2011). In a research conducted to test the effect of
crocin coated nanoparticles on precancerous livers in mice showed a significant
regression of the precancerous lesions and upregulation of apoptosis (El-Kharrag et
al., 2017). Another research showed crocin’s ability to prevent early lesions of liver
cancer in HepG2 cells and Wistar rats (Amin et al., 2016). Crocin has been shown to
inhibit proliferation of colorectal cancer HCT116 wild type and HCT116 p53-/- cell
lines, crocin treatment induced an autophagy-independent classical programmed cell
death(Amin et al., 2015)

1.5 Cancer Research
The field of cancer research is rapidly growing with new insights and
perspectives discovered on a fast base. Molecular biology has provided a unique
perspective to cancer research and offered novel approaches to cancer treatments. In
labs, in vivo and in vitro approaches are used to evaluate the effectiveness of different
treatment strategies. In vitro technique is a low-costing tool to screen cancer therapies,
however the 2-dimensional structure of cells lack the accurate representation of a
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tumor microenvironment in a living organism (Katt et al., 2015). Testing on living
organisms such as rats, rabbits, and mice are referred to as in vivo analysis. Assessing
cancer treatments on a tumor inside a living animal more closely simulates the
processes that happen in the human body (Lackie, 2010). Cancer can be induced in
these living organisms in several methods including; xenografting, chemical
carcinogens, viruses, and gene editing.

1.5.1 Diethylnitrosamine
The strong carcinogenic ability of N-nitroso compounds was first discovered
in early 1937 when it was reported that dimethynitrosamine (DMN) could be one of
the agents causing liver damage in men. Multiple experimentations on rats have
demonstrated its capability to cause severe liver necrosis and showed the hepatotoxic
and carcinogenic effects of the N-nitoroso compounds including diethylnitrosamine
(DEN) in rats, mice, rabbits, guinea pigs and dogs. Now using DEN to induce liver
cancer in animals is a well-established and effective model (Tolba et al., 2015).

1.5.2 Diethylnitrosamine and Animal Models
The increasing risks and high incidence of liver cancer is driving more research
to understand the cellular and molecular mechanisms involved in such a disease.
Therefore, the need to develop animal models that simulate the actual disease in
humans are vital (Hasenfuss et al., 2014). Traditional models include fasting the
animals for 96 hours followed by with refeeding the animals which helps in stimulating
cell proliferation and DNA damage, after that a single high dose of a carcinogen
(diethynitrosamine) and multiple doses of a chemical promoter (acetylaminofluorene)
are administered to induce the formation of tumors (Tomasi et al., 1999). On one hand,
their easy application and low cost are some of their advantages, on the other hand, the
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tumors formed do not mimic the conditions and the inflammatory process that
proceeds liver cancer. Thus making those models unreliable to asses and evaluate the
effectiveness of new cancer treatments. New protocols to induce liver cancer in
animals involving the use of multiple smaller doses of chemical carcinogen which in
turn mirror disease progression in liver cancer patient by imitating the inflammatory
process that often leads to fibrosis and cirrhosis and ending up with the formation of
malignant tumors (DePeralta et al., 2016).

1.6 Objectives of the Study
The aim of this study is to examine crocin’s therapeutic effects against
chemically induced hepatocellular carcinoma. That will involve the following steps:
1. Carcinogenesis: Chemical induction of HCC in male Wistar rats.
2. Treatment with crocin.
3. Assessment of biomarkers of liver functions.
4. Histopathological evaluation of liver tissues.
5. Western blotting examination of key tumor markers.

1.7 Hypothesis
We hypothesize that crocin will have a therapeutic effect against DEN-induced
hepatocellular carcinoma in vivo.
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Chapter 2: Materials and Methods
2.1 In vivo Model
2.1.1 Animals
Male Wistar rats were obtained from the animal research facility at the College
of Medicine and Health Sciences, UAE University. Initially animals weighed around
110 gm, they were housed at 12 hours’ light/ dark cycles at 24 – 26 °C and maintained
on standard laboratory animal diet with food and water ad libitum. All animal
experimentations were carried out in accordance with and the approval of the Animal
Research and Ethics Committee of the College of Medicine and Health Sciences,
UAEU (Approval No. A8-15).

2.1.2 Experimental Design
2.1.2.1 Carcinogenesis
In this study, 4 weeks old male Wistar rats were used. The rats were randomly
divided into two groups; Control group (n=6) that received 1x PBS via intraperitoneal
(i.p.) injection; Experimental group that were injected with DEN at 50 mg/kg b. wt.
(Sigma Aldrich, USA) dissolved in PBS once a week for 16 weeks via i.p. This HCC
induction protocol was modified from the protocol described by (DePeralta et al.,
2016; Schiffer et al., 2005).

2.1.2.2 Treatment Protocol
At week 16, HCC was established in the experimental group, the animals were
divided into 4 groups (n= 8) as follows: HCC alone, HCC + crocin, HCC+ sorafenib,
HCC+ crocin + sorafenib (Figure 4). From week 17 to week 19 (add NUMBER of
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WEEKS) treatment with crocin and/or sorafenib has started once a day for five days a
week. All drugs were orally administered with intragastric (gavage) tube. Doses and
route of administration follow what has been previously used in literature.
During the first week of the experiment, PBS group received 1x PBS via i.p.
injection for the entire duration of the experiment. The HCC experimental groups were
however injected with 50 mg/kg b.wt. DEN (Sigma Aldrich, USA) dissolved in PBS
once a week for 16 weeks. At week 17, treatments with crocin and sorafenib were
administered 5 times a week by oral gavage until week 19. All applied doses were
selected based on available literature (Alsaied et al., 2014; Amin et al., 2011).
In the HCC + crocin group, crocin (Sigma Aldrich, USA) was administered at
a dose of 200 mg/kg b.wt. For HCC + sorafenib group, sorafenib (Carbosynth Limited)
was administered at a dose of 10 mg/kg b.wt. Animals of the HCC + crocin + sorafenib
group received crocin at 200 mg/kg b.wt., followed immediately with sorafenib at 10
mg/kg b.wt. Crocin was diluted with 1x PBS. A 0.3% solution of DMSO was used to
dissolve the sorafenib. Oral LD50 of crocin is 1-5 g/kg b.wt. for male Wistar rats
delivered via i.p. injection (Hosseini, Razavi, & Hosseinzadeh, 2018). At the end of
the experimental period and after a 24-hour post last drug administration, animals were
euthanized using Diethyl ether and sacrificed and dissected under controlled
conditions. Blood and liver tissue samples were collected and stored either at room
temperature in buffered formalin for histological analysis or at -80 °C in PBS for
biochemical and immunoblotting analyses.
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Figure 4: Experimental design

2.2 Sample preparation
2.2.1 Blood Samples
In order to collect blood samples, the rats were euthanized and then
decapitated and blood was collected in collection tubes (BD Vacutainer). To separate
the serum from the whole blood the samples were centrifuged at 1200 rpm for 10
minutes. Serum was collected and flash frozen in liquid nitrogen and then stored at 80°C for further investigation.

2.2.1.1 Biochemical Analysis
Levels of liver enzymes Alanine Transaminase (ALT), and Aspartate
Aminotransferase (AST) were assessed using a colorimetric assay available
commercially. The kits were purchased from Abcam and the protocol provided was
followed to measure the concentration of ALT and AST using the Promega GloMax
Discover microplate reader (Figure 5).
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2.2.2 Liver Samples
The liver tissues were cleaned using PBS and photographs of the liver gross
were taken. Each collected liver was then divided into two parts, one part was stored
in empty Eppendorf tubes and immediately flash frozen in liquid nitrogen and later
stored in -80°C for further investigation. The other part of the liver was stored in a
10% solution of neutral buffered formalin at room temperature for histopathological
examination (Figure 5).

Figure 5: Diagrammatic representation of blood and liver samples that were used to
asses several parameters

2.2.2.1 Histopathological Preparation
Liver tissue samples were kept in 10% solution of neutral buffered formalin for
fixation in order to preserve the integrity of the tissue. Following this step, the tissues
were cut into 3µm thick sections, tissue sections were dehydrated to remove the water
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content of the tissue, this process was achieved using a series of ethanol solutions with
increasing concentration. After that xylene was used to clear any ethanol that remained
in the tissue to allow the next step to be successful. The final step was to prepare the
paraffin blocks by embedding the tissue sections in paraffin wax that allows the wax
to infiltrate the tissue. These blocks were then cut into 3 µm thick sections. To observe
morphological changes at the cellular levels two stains were used, H&E and reticulin
staining and the protocol were followed according to the manufacturer’s instructions
(Abcam) and the tissue slides were then observed and examined under light
microscopy (Alturkistani et al., 2016). All liver tissue samples were blindly examined
by a pathologist from Tawam Hospital – UAE to evaluate the effectiveness of the
carcinogenesis model and the impact of treatments used in this study.

2.2.2.2 Western Blot Analysis
Liver tissue samples (10 mg) were homogenized in cold RIPA buffer (Sigma
Aldrich, USA) 2 µl of protease inhibitor and of phosphatases inhibitor were added to
the homogenizing buffer (Sigma Aldrich, USA). Protein concertation of each liver
sample was determined using the Bradford method (Bio-Rad, Hercules, CA) with the
Promega GloMax Discover. In order to blot the proteins into the gel, 2mercaptoethanol, a loading dye, was added to the cell lysate produced from the
homogenization of liver tissues. The mixture of the lysate and loading dye was then
loaded into the SDS-PAGE gel. Variations of gel percentages were used according to
the size of protein to be determined. Following the separation of the protein content of
each sample on the SDS-PAGE gel, proteins were transferred onto a PVDF membrane
and blocked in 5% BSA in TBST or a 5% (w/v) non-fat milk at room temperature for
one hour. After the blocking stage, the membranes were incubated with primary anti-
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body overnight at 4°C. In this study, the primary anti-bodies selected here were antiProliferating Cell Nuclear Antigen (PCNA), anti-caspase-3 (Cell Signaling
Technology

Inc.),

anti-caspase-9

(Nous

Biologicals),

anti-PolyADP-ribose

Polymerase (PARP), anti-Bcl-2, anti-Bax (Santa Cruz). Following the overnight
incubation with primary antibodies, the membranes were extensively washed with
TBST and re-probed with secondary anti-bodies including anti-rabbit IgG (Cell
Signaling Technology, Inc, MA, USA) and anti-mouse IgG, and conjugated
horseradish peroxidase for 1 hour at room temperature. Protein bands then detected
using a chemiluminescence solution known as WesternSure PREMIUM, the signal
was detected and visualized using the Bio-Rad ChemiDoc XRS+ System. The
intensity of the band was measured using the ImageJ software (Amin et al., 2011). The
internal control used was total protein which was stained using the SYPRO Ruby
protein gel stain following the protocol instructed by the manufacturer (Thermo Fisher
Scientific) (Aldridge, Podrebarac, Greenough, & Weiler, 2008; X. Hu et al., 2016;
Mahmood & Yang, 2012).

2.2.2.2.1 Total Protein
Housekeeping proteins are used as the controls for every western blot analysis.
Because of their stable expression in tissues, they are great indicators to validate the
integrity of the protein samples loaded into the SDS-PAGE gel, therefore accurately
reflecting the amount of proteins in the samples. Current research has investigated the
ability of these housekeeping proteins to remain stable under different experimental
conditions. In this study, various housekeeping proteins were used as loading controls
including GAPDH, β-actin, β-tubulin and were found to be inconsistent. A research
paper published in 2003 highlights this issue, it indicated that the gene expression of

16
commonly used loading controls including GAPDH and β-actin was increased and it
varied between 7- to 23-fold, and interestingly, this was shown in cancer tissues (Kim
& Kim, 2003). Therefore, an alternative approach was used to resolve this issue. Total
protein was utilized as the loading control; this protocol measures the whole protein
content of a sample rather than relying on one protein. This has been proven to be a
reliable loading control in colorectal cancer and HCC (Aldridge et al., 2008; X. Hu et
al., 2016).
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Chapter 3: Results
3.1 Liver Enzymes in Serum
Liver function analyses were carried out to assess the level of enzymes released
by the hepatocytes into the blood stream. These levels reflect on the integrity and
functionality of the liver. When the liver is damaged, these enzymes are extensively
released from the hepatocyte. ALT and AST are the most commonly checked enzymes
to evaluate the efficiency of the liver.

3.1.1 Effect of Treatment on Serum Enzymes
ALT (P<0.01) and AST levels were significantly increased in the HCC group
in comparion to the control group, thus indicating the severity of the liver damage
caused because of tumor formation (Figure 6). Treatment with crocin alone and
combined with sorafenib showed a decrease in the level of ALT (P<0.01) in
comparison to the HCC group. Monotherapy with crocin and combined treatment with
both crocin and sorafenib had significantly decreased levels of ALT (P<0.05) in
comparison to the sorafenib alone group (HCC + sorafenib).
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Figure 6: Activity of liver enzymes (AST, ALT) measured in serum (n=6).
Statistical significance was determined using Microsoft Excel Data Analysis Too
Pack, t-test; two-sample assuming equal variance (a versus PBS, b versus HCC, c
versus HCC +SB; *P < 0.05, **P<0.01, P<0.001).
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3.2 Anti-cancer Effect of Crocin on DEN-Induced HCC in Rats
3.2.1 Macroscopic Appearance of Liver
Animal livers in the PBS group had normal liver structure and livers had
normal size and texture and glossy dark brown color with no macroscopic lesions
observed. HCC livers showed a notable pale color and appearance with multiple
lesions that were apparent to the naked eye (Figure 7). Treated livers appeared less
stressed in comparison to the HCC group. Therapeutic administration of drugs to
DEN-induced HCC rats had restored the normal morphology of the liver compared to
those in the HCC alone group. Treatment with crocin alone (HCC + CR) and with both
crocin and sorafenib (HCC + CR + SB) has reduced the number of lesions in
comparison to the HCC animals. Crocin treated animals had significantly lower
numbers of lesions in comparison to the livers of sorafenib alone (HCC+ SB)
(Figure 8).

Figure 7: Representative images of animal livers to show the therapeutic anti-tumor
effect of drugs used.
PBS, DEN-induced HCC rats (HCC) or treated with crocin (HCC CR), sorafenib
(HCC SB) separately or as combined (HCC CR + SB).
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Figure 8: Quantitative analysis of number of liver nodules from DEN-induced HCC
in rats untreated and other treated groups.
(HCC alone group), or treated with sorafenib (HCC + sorafenib), crocin (HCC
Crocin) individually or as a combination (HCC crocin + sorafenib).
Statistical significance was determined using Microsoft Excel Data Analysis Too
Pack, t-test; two-sample assuming equal variance (a versus PBS, b versus HCC; *P <
0.05, **<0.01).

3.2.2 Histopathological Evaluation of Liver
Histopathological examination of liver tissue (Figure 9) was done to further
investigate the therapeutic effects of crocin on DEN-induced HCC in rats. Liver
sections were examined under light microscope to obtain representative images. In
order to visualize cellular components and tissues under the microscope, sections were
stained using Hematoxylin (H) which stains the nucleus with a blue color and with
eosin (E) which stains the cytosol with a pink color. H&E are the standard stains used
in histology (Chan, 2014). Control PBS group showed normal architecture and
histology of animal liver, normal liver lobule with a central vein, hepatocytes are
arranged in normal spans, radiating from the central vein. Histological examination
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also revealed that the intact core and normal vascular relationships between the portal
tract and hepatic venules were evident.
Histological evaluation of HCC groups demonstrated abnormal cell
morphology, that are consistent with the progression of HCC, where the liver cords
appeared wider than normal liver plates, the normal architecture of the lobules were
lost. Crocin alone or in combination with sorafenib restored to a great degree the
normal architecture of the liver in HCC groups.

Figure 9: Histopathological evaluation of livers from control and experimental
groups.
Control group (PBS), DEN-induced HCC in untreated rats (HCC) or treated with
crocin (HCC CR), sorafenib (HCC SB) individually or as adjuvants (HCC CR SB).
High magnification 40x and low magnification at 10x. Arrows point to representative
areas of AHF).
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3.2.2.1 Reticulin Staining
Reticulin is an immunostain that is mostly used to investigate the liver
histopathology. It helps visualizing the reticular fibers, which is a useful tool in
diagnosing well differentiated HCC (Hong, Patonay, & Finley, 2011). Liver sections
from all groups were processed and stained with reticulin and examined with light
microscope (Figure 10). Control PBS groups demonstrated a normal reticular network.
Experimental HCC group showed apparent collapse of the reticulin network.
Monotherapy with crocin alone (HCC + crocin) and as an combination with sorafenib
(HCC+ crocin + sorafenib) has recovered the damage done by the DEN-induction of
cancer, fiber breakage appeared less often in comparison to HCC groups.
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Figure 10: Reticulin staining livers from all groups. Sections from control groups
(PBS), DEN-induced HCC in untreated rats (HCC) or treated with crocin (HCC CR),
sorafenib (HCC SB) individually or as adjuvants (HCC CR SB).
High magnification 40x and low magnification at 10x. Arrows point to reticulin
fibers.
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3.2.3 Role of Crocin in Proliferation
Western blot analysis and quantification of PCNA highlights the significant (P
< 0.01) increase in PCNA expression in HCC animal livers in comparison to the
control group, while treatment with crocin (P < 0.01) alone and as an adjuvant with
sorafenib (P < 0.01) has significantly lowered the expression of PCNA. The
combination of crocin and sorafenib has significant (P < 0.001) lower levels of PCNA
compared to crocin alone or sorafenib alone (Figure 11).
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(a)

(b)

Figure 11: Crocin inhibits proliferation of induced HCC.
(a) Western blot where PCNA was assessed in control (PBS) and experimental groups
DEN-induced HCC (HCC) or treated with crocin (HCC CR), sorafenib (HCC SB)
individually or as adjuvants (HCC CR SB). (b) Quantification plot where signals were
quantified using ImageJ and normalized in accordance to the total protein from the
liver. Results are expressed as mean ±SD for n=4 animals from each group. Statistical
significance was determined using Microsoft Excel Data Analysis Tool Pack t-test:
two-sample assuming equal variance. a versus PBS, b versus HCC; *P<0.05,
**P<0.01, ***P<0.001.
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3.2.4 Role of Crocin on Apoptosis
In this study, western blot analysis (Figure 12) showed that treatment with
crocin lead to the activation of the intrinsic apoptotic pathway. This has been
concluded through measuring the expression of key players in the intrinsic pathway
including Bax, Bcl-2, PARP, caspase-3 and caspase-9

Figure 12: Crocin activates the intrinsic apoptotic pathway of DEN-induced HCC.
Western blot analysis of the key proteins involved in the intrinsic apoptotic pathway
(PARP, Pro-Caspase-9, Pro-Caspase-3, Bax, Bcl-2) of livers from control and
experimental groups. Control group (PBS), DEN-induced HCC in untreated rats
(HCC) or treated with crocin (HCC CR), sorafenib (HCC SB) individually or as
adjuvants (HCC CR SB).
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Figure 13: Quantification of Pro-Caspase-3, Pro-Caspase-3, PARP from control and
experimental groups.
Control group (PBS), DEN-induced HCC in untreated rats (HCC) or treated with
crocin (HCC CR), sorafenib (HCC SB) individually or as adjuvants (HCC CR SB).
Band intensities were quantified using ImageJ and normalized in accordance to the
total protein from the liver. Results are expressed as mean ±SD for n=4 animals from
each group. Statistical significance was determined using Microsoft Excel Data
Analysis Tool Pack t-test: two-sample assuming equal variance. a versus PBS, b versus
HCC; *P<0.05, **P<0.01, ***P<0.001.
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Figure 14: Quantification of Bax, Bcl-2, Bax/Bcl ratio from control and experimental
groups.
Sections from control groups (PBS), DEN-induced HCC in untreated rats (HCC) or
treated with crocin (HCC CR), sorafenib (HCC SB) individually or as adjuvants (HCC
CR SB). Band intensities were quantified using ImageJ and normalized in accordance
to the total protein from the liver. Results are expressed as mean ±SD for n=4 animals
from each group. Statistical significance was determined using Microsoft Excel Data
Analysis Tool Pack t-test: two-sample assuming equal variance. a versus PBS, b versus
HCC; *P<0.05, **P<0.01, ***P<0.001.
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The role of crocin on the apoptotic pathway of DEN-induced HCC in animals
was investigated by assessing the expression of key markers involved particularly in
the mitochondria-mediated (intrinsic) apoptotosis. The data collected here shows that
treatment with crocin had a significant (P < 0.05) effect on increasing the expression
of the pro-apoptotic protein Bax which plays an important role in the activation of the
pathway while the expression of the anti-apoptotic protein Bcl-2 was significantly (P
< 0.05) decreased compared to the HCC group. Data demonstrated that crocin given
as a combination with sorafenib had a stronger (P<0.05) effect on the DEN-induced
HCC animals compared to crocin alone or sorafenib alone. Multiple western blot
experiments were completed to thoroughly investigate the role of crocin on apoptosis
where results have confirmed that pro-caspase-3, pro-caspase-9, and PARP the
activation of the intrinsic apoptotic pathway. The expression of these proteins was
significantly (P<0.01, P<0.01, P<0.001, respectively) decreased in crocin treated
group and when crocin was used in combination with sorafenib compared to the HCC
group alone proceeding treatment with crocin and with both crocin and sorafenib
(Figure 13, Figure 14).
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Chapter 4: Discussion
4.1 Crocin Ameliorates Liver Function by Reducing levels of ALT and AST
The liver is a complex organ that carries out essential functions that maintain
homeostasis. Key biological processes that take place in the liver include the uptake,
metabolism, and the excretion of various foreign materials. Liver is also involved in
the immune response, phagocytosis and removal of microorganisms. It is also the site
for metabolizing proteins, carbohydrates and fats (Hoekstra et al., 2013). Routine
analysis of the liver function includes checking the levels biomarkers including ALT
and AST. These levels significantly reflect the level of liver damage and dysfunction.
ALT is found in high concentrations in the liver, however, it is also found in other
locations including the kidney and heart. In the cytoplasm of hepatocytes, it plays a
key role as a catalyst in the transamination reaction. ALT is also involved in the
transamination reaction and found in the mitochondria and cytoplasm of hepatocytes,
however it is mainly concentrated in heart tissue. Slight damage to the liver will
significantly elevate the levels of ALT and AST in the serum (Gowda et al., 2009).
Research investigating the chemo-preventative effect of saffron on DENinduced HCC showed that saffron had significantly restored the levels of ALT and
AST in rats (Amin et al., 2011). Treatment with sorafenib had a similar effect on the
levels of these liver enzymes. ALT and AST were notably lower in the treated groups
indicating amelioration of liver function (Lv et al., 2017). In the present study, the
levels of liver serum enzymes both ALT and AST were higher in the DEN-induced
HCC group in comparison to the PBS control group, which directly correlate with
severe liver damage. Data collected in this investigation showcases that monotherapy
with crocin had a great impact on lowering the levels of both ALT and AST in the
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blood in comparison to DEN-induced HCC rats (Figure 6). Combination therapy with
both crocin and sorafenib had a significantly stronger impact on decreasing the levels
of these serum enzymes in comparison to sorafenib alone (P<0.05). This fact indicates
the both crocin and sorafenib work synergistically and with better efficacy to
ameliorate the DEN-induced damage to the livers (Figure 6).

4.2 Crocin’s Impact of Ameliorating Histological Changes
Liver is divided into lobules, each one of these lobules has a hexagonal
structure with a central vein and branches of hepatic artery, and bile duct. Hepatocytes
are normally arranged in single-celled thick plates that are radiating from the central
vein (Thoolen et al., 2010). To assess the effectiveness crocin, liver biopsies were
analyzed. Liver biopsies are traditionally performed as a diagnostic tool to identify the
cause and the severity of liver diseases (Cong et al., 2016). In this study, macroscopic
nodules were observed in livers collected from DEN-treated animals as seen in (Figure
7). Histopathological examination of livers in DEN-induced animals revealed clear
features of HCC lesions showcasing trabecular pattern and characterized by clear
cytoplasm. The normal hexagonal shape of hepatocytes is lost. Plates are no longer
arranged in single- celled thick plates. Lymphocytic infiltration was observed. All of
which indicate the development of HCC. Similar results were observed in other studies
as well (Moreira et al., 2015). Monotherapy with crocin alone and as an adjuvant with
sorafenib has a significant impact on lowering the numbers of liver nodules observed
(Figure 8). Research using crocin coated D-MNPs nanoparticles to treat DEN-induced
precancerous liver in mice showed that livers of animals treated with crocin showed
apparent recovery of liver histology (El-Kharrag et al., 2017).

32

4.2.1 Crocin’s Impact on the Reticular Network
The connective tissue is one of the four main types of tissues in the body. It has
an important role in immune defense, growth and repair, and providing mechanical
support. Connective tissue provides a backbone for epithelial tissue. It is composed
mainly of the extracellular matrix and different types of cells. There are three different
types of extracellular fibers including collagen, elastin and reticular fibers. Reticular
fibers are mainly made up of type III collagen forming thin reticular network mainly
found in the liver and muscle fibers (King, 2015). Reticulin staining has been shown
to be a helpful tool in differential diagnosis to distinguish between well-differentiated
HCC and benign liver lesions. In the case of HCC the reticular network is either
completely lost or has an abnormal pattern. That pattern includes widen trabeculae
with an increase in the thickness of cell layers (Hong et al., 2011).
Study conducted on rats aimed to uncover the changes in reticular fiber patterns
in hepatic fibrosis induced by thioacetamide and bile duct ligation. A week after the
induction of fibrosis the results showed a marked decrease in the reticular fiber
suggesting the collapse of the reticular fiber network in response to liver damage
reticular network (Wen et al., 2016). A paper reviewing the currently used
inmmunohistochemistry stains for differential diagnosis of HCC revealed the reticulin
stain of biopsy of HCC patients showed the loss of reticulin which confirms the stain’s
ability to be reliably used to diagnosis HCC and to differentiate the different
phenotypes of liver cancers (Brunt, 2012).
In this study, liver sections were processed and stained with reticulin and
examined under light microscope (Figure 10). PBS groups demonstrated an intact
reticulin network with thin plates. Experimental HCC group showed abnormal patterns
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in the areas of HCC nodules, showing thicker plates with apparent collapse of the
reticulin network. Monotherapy with crocin alone (HCC + crocin) and as an adjuvant
with sorafenib (HCC+ crocin + sorafenib) has significantly recovered the damage done
by the DEN-induction of cancer; fiber breakage appeared less often in comparison to
HCC groups. Results in the present study are consistent with the studies mentioned
above. Was sorafenib ever used to assess reticulin damage in HCC, any study that link
reticulin with sorafenib should be integrated and discussed here.

4.3 Crocin’s Anti-Cancer and Anti-Proliferative Impact on DEN-Induced
HCC in Rats
4.3.1 Crocin Impact on Proliferation
PCNA has been found to play a vital role in many cellular processes including
DNA replication, DNA repair, and cell cycle progression. Mutations during DNA
replication will reflect in the post-translational modification of PCNA which in turn
alters the function of PCNA (Stoimenov & Helleday, 2009). PCNA is a marker for
proliferation, due to its role during replication. During replication PCNA molecules
form a sliding clamp around the DNA helix, creating a platform to regulate the process
of replication (Wang, 2014). Its expression is increased in breast and liver cancer
metastasis. PCNA peaks during the S phase, therefore making it an indicator of cellular
proliferation (Hu et al., 2017). Assessing the level of PCNA expression is used as a
diagnostic and a prognostic tool to evaluate cancers. A study conducted on breast
cancer patients revealed high expression of PCNA in cancer tissues of the patients in
comparison to the adjacent normal tissues (Qiu et al., 2017).
Other investigation utilizing Sprague Dawley rats to evaluate the anti-tumor
effects of bee honey showed high levels of PCNA expressed in the DEN-induced
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animals in comparison to the control groups. In the present study, western blot analysis
demonstrated the levels of PCNA in DEN-induced HCC animals was significantly
higher in comparison to the control groups. Treatment with crocin and with both crocin
and sorafenib lead to the decrease in the expression of PCNA (Figure 11). Crocin has
been found to inhibit cell proliferation and induce apoptosis in A549 and SPC-A1 lung
cancer cells (Chen et al., 2015). In another research on breast cancer cells, crocin
inhibited proliferation by disrupting the microtubule network (Hire et al., 2017).
Research investigating the anti-tumor effects of crocin on treating melanoma in
C57BL/6 mice that were transplanted with B16G10 cancer cells showed that after a 21
days treatment period with crocin, the tumor was reduced and the survival time was
significantly increased (Bakshi et al., 2017).

4.4 Western Blot Analysis
4.4.1 Crocin’s Role in Inducing Apoptosis
Apoptosis, programmed cell death, is one of the most studied topic in cellular
biology. It is an intricate process that happens both in physiological and pathological
conditions. Apoptosis is essential to maintain homeostasis and regulate cellular
development. Imbalances in apoptosis will contribute to the development of many
disorders including autoimmune diseases and cancer. In the case of cancer, the
equilibrium between cell-death and cell-division is lost. This problem arises because
cancer cells are extremely smart and adaptive, they have the ability to skip the death
signal and continue multiplying endlessly. This leads to the formation of clumps of
mutated cells; tumors (Wong, 2011).
Two pathways are involved in activation of apoptosis: the extrinsic pathway
which is switched on by different death receptors and the intrinsic pathway which is
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regulated by the mitochondria and leads to the release of apoptotic factors. Enzymes
involved in both pathways play a key role in the activation and deactivation of
apoptosis. The most important family of these enzymes are known as ‘’caspases’’.
They mainly function to cleave certain substrates leading to their activation (Yaacoub,
Pedeux, Tarte, & Guillaudeux, 2016). This study focused on investigating the intrinsic
apoptotic pathway.
The intrinsic pathway is activated by either extra-cellular or intracellular
stressors including; hypoxia, DNA damage, oxidative stress). These stimuli will cause
changes in the permeability of the outer mitochondrial membrane which will cause the
release of cytochrome c. This permeability is controlled by the BCL-2 proteins family,
specifically Bcl-2 and Bax. Once released cytochrome c will activate Apaf-1 and procaspase-9 forming an apoptosome. Accumulation of pro-caspase-9 will activate the
initiator caspase-9. Under normal circumstances the pro-apoptoic protein Bax binds
with the anti-apoptotic protein Bcl-2 to control mitochondrial membrane permeability.
Once cytochrome c is released it will activate executioner caspase -3 and the initiator
caspase -9 (Ding et al., 2010, p. 2; Elmore, 2007; Jayakiran, 2015).
Under normal physiological conditions PARP functions to detect and repair
DNA damage and plays an essential role in the regulation of apoptosis. Once activated,
PARP will transfer NAD+ and binds PAR into DNA polymerase in order to repair
problems that arise during DNA replication. Excessive activation of PARP will switch
on the intrinsic apoptotic pathway. PARP is a pro-apoptotic signal, after PARP
activation, PARP will move from the nucleus into the cytosol to interact with the outer
mitochondrial membrane. This process will release apoptosis-inducing factors and the
cell undergoes apoptosis (Gungor-Ordueri et al., 2019; Y. Wang et al., 2011).
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Apoptosis is a key player in driving carcinogenesis and making cancer cells
chemo-resistant to conventional therapeutic approaches. Cancer’s ability to skip
apoptosis is one of the prominent hallmarks of cancer (Hassan et al., 2014). Research
conducted on lung cancer cells tested the effect of saffron on inducing apoptosis on
A549 cells and found that levels of caspases was upregulated in saffron treated cells.
This suggests the activation of apoptosis in cancer cells which is attributed to treatment
with saffron (Samarghandian, Borji, Farahmand, Afshari, & Davoodi, 2013). In
another study, DEN-induced HCC in Wistar rats that were treated with melatonin has
been shown to activate apoptosis. This has been shown via the upregulation in the
levels of caspases and the cleaved PARP, melatonin led to the increase in the Bax/Bcl2 ratio (Moreira et al., 2015). Research investigating the effect of glycerol treatment
in Wistar rats showed the apoptosis was increased and it has been shown through the
activation of caspase-3 and the increase of the Bax/Bcl-2 raito as well (Capiglioni et
al., 2018).Another study investigating the effect of safranal, another main bioactive
molecule in saffron has been shown to induce apoptosis in HepG2 cells, where the
ratio of Bax to Bcl-2 was increased, caspase-3, caspase-9, were upregulated (Al-Hrout
et al., 2018). Another research confirms crocin’s ability to activate apoptosis showed
that using crocin as a preventative measure against lesions of liver cancer in Wistar rat
significantly upregulated apoptosis in the livers of treated animals, this was
demonstrated through histological examination with M30 CytoDeath anti-body (Amin
et al., 2016). A research using crocin-coated D-MNPs showed that percent increase in
cell death with crocin D-MNPs was highly significant when compared to DNEinjected mice (El-Kharrag et al., 2017). Crocin has been shown to induce an
autophagy-independent classical programmed cell death in colorectal cancer in
HCT116 wild type and HCT116 p53-/- cell lines(Amin et al., 2015).
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In this study, western blot analysis (Figure 12, Figure 13, Figure 14)
demonstrated that treatment with crocin triggered the activation of the intrinsic
apoptotic pathway. This has been concluded through measuring the expression of key
players in the intrinsic pathway including Bax, Bcl-2, PARP, caspase-3 and caspase9. Results in the current study showcased the upregulation of Bax and the
downregulation of Bcl-2 as a result of the treatment with crocin in comparison with
HCC rats. Therefore, the increase in the Bax/Bcl-2 ratio seemed to be support this
conclusion. Intriguingly, adjuvant treatment of crocin and sorafenib seemed to have a
better effect in the activation of the intrinsic pathway over the treatment with crocin
alone or sorafenib alone. Further investigation in the intrinsic pathway revealed the
remarkable decrease in the expression of whole PARP, pro-caspase-3, and procaspase-9 in crocin treated rats in comparison with HCC animals. A study done to
evaluate saffron’s anti-apoptotic effect on colorectal cancer cell lines demonstrated
saffron induced p53-depedent caspase -3 activation in HCT116 cells (Bajbouj et al.,
2012)
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Chapter 5: Conclusion
Based on the biochemical, histological, and molecular markers evaluated in
this study, saffron-based crocin proves to be a potent novel therapeutic candidate
against DEN-induced HCC. Crocin has also attested its significant anti-proliferative
and an anti-tumor effects.
This study also introduces crocin for the first time as a combination therapy
with sorafenib. Further investigation is required to unravel other molecular pathways
involved in crocin’s therapeutic effect not only against HCC but against other
gastrointestinal cancers as well.
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